The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.
Valeo Pharma: drug for Covid-19 therapy receives approval
"
The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system," commented Steve Saviuk, President and CEO of
Valeo Pharma (CSE: VPH). Redesca is a heparin product. Such active ingredients have been tried and tested for many years and are traditionally used in the treatment of thrombosis.
Recently, the World Health Organization (WHO) announced that Redesca could also be used in the treatment of Covid-19 to prevent further complications associated with infection.
The market for such products in Canada is currently worth approximately CAD 200 million. Valeo Pharma expects to gain market share with its new product. "We expect Redesca to play a major role in the achievement of our growth objectives," Saviuk said in a Company release.
Redesca, the newly approved drug, is a biosimilar, i.e., a generic version of a biopharmaceutical. Since this type of medication is usually cheaper than originals and healthcare systems are in a saving mode, biosimilars and generics are increasingly in demand. Valeo Pharma's shares have also been in demand recently: last month alone, the value increased by around 25%.
The latest news increases the likelihood that the Company's ambitious growth targets will be achieved - this could also be a good sign for the share.
CureVac: Fantasy knows no bounds
The Tübingen vaccine pioneer,
CureVac (NASDAQ: CVAC), is doing almost frighteningly well:
in the past month alone, the paper has increased by a whopping 150%. In the opinion of many traders and market experts, such a development calls for a correction. But CureVac has developed a vaccine against the coronavirus and is also a leader in mRNA technology, which enables the human body to produce its own medicine.
Beyond the pandemic, the market for CureVac shares is already spinning further and further: Will there soon be a vaccination against cancer? Will diseases of civilization or Alzheimer be defeated soon?
Given the development of vaccines in record time, it seems that there are currently no limits for biotech stocks. However, investors should be cautious and limit their risk given the stocks rapid gains. At the moment, it is advisable not to invest in the stock.
Moderna: Money shower ahead?
The situation is similar with
Moderna (NASDAQ: MRNA). The shares of the US biotech Company are also benefiting from the effective vaccine presented a few weeks ago.
Like CureVac, Moderna is also focusing on mRNA technology in the hope of being able to treat other diseases or produce a vaccine against them in the future. Given the promising clinical results and the high efficacy of the vaccines of Moderna and CureVac, both Companies could be in for a real windfall.
Cautious investors pay attention to the drop in price
If the biotech pioneers invest these funds in the development of new products, the growth of Moderna and CureVac could increase. But despite this fantasy, investors should not think too far into the future at current valuation levels. As with CureVac, Moderna is currently subject to greater risk for investors.
Companies such as the Canadian Valeo Pharma or Sartorius (FSE: SRT3), the Goettingen-based supplier of laboratory equipment, may not exude as much fantasy, but they have a lower fall.
CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our ´
Conflict of Interest & Risk Disclosure´.